Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/effect-of-hydroxychloroquine-on-clinical-status-at-14-days-in-RtiswJ0ELL
References (34)
-
A. Bhimraj, R. Morgan, A. Shumaker, L. Baden, V. Cheng, K. Edwards, Jason Gallagher, R. Gandhi, W. Muller, Mari Nakamura, J. O’Horo, R. Shafer, S. Shoham, M. Murad, R. Mustafa, S. Sultan, Y. Falck-Ytter (2022)
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
-
P. Horby, M. Mafham, L. Linsell, Jennifer Bell, N. Staplin, J. Emberson, M. Wiselka, A. Ustianowski, E. Elmahi, B. Prudon, T. Whitehouse, T. Felton, John Williams, J. Faccenda, J. Underwood, J. Baillie, L. Chappell, S. Faust, T. Jaki, K. Jeffery, W. Lim, A. Montgomery, K. Rowan, J. Tarning, J. Watson, N. White, E. Juszczak, R. Haynes, M. Landray, Recovery Group (2020)
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19The New England Journal of Medicine, 383
-
E. Rubin, D. Harrington, Joseph Hogan, C. Gatsonis, L. Baden, M. Hamel (2020)
The Urgency of Care during the Covid-19 Pandemic — Learning as We GoThe New England Journal of Medicine
-
J. Sanders, M. Monogue, T. Jodlowski, J. Cutrell (2020)
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.JAMA
-
Nicholas Mercuro, C. Yen, David Shim, T. Maher, Christopher McCoy, P. Zimetbaum, H. Gold (2020)
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).JAMA cardiology
-
C. Spinner, R. Gottlieb, G. Criner, J. López, A. Cattelan, A. Viladomiu, O. Ogbuagu, P. Malhotra, K. Mullane, A. Castagna, L. Chai, M. Roestenberg, O. Tsang, E. Bernasconi, Paul Turnier, Shan-Chwen Chang, Devi SenGupta, R. Hyland, A. Osinusi, H. Cao, C. Blair, Hongyuan Wang, A. Gaggar, D. Brainard, M. Mcphail, S. Bhagani, M. Ahn, A. Sanyal, G. Huhn, F. Marty (2020)
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.JAMA
-
Singer (2016)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA, 315
-
Xueting Yao, F. Ye, Miao Zhang, Cheng Cui, Baoying Huang, P. Niu, X. Liu, Li Zhao, Erdan Dong, Chunli Song, S. Zhan, R. Lu, Haiyan Li, W. Tan, Dongyang Liu (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
-
A. Kasuya (1990)
EuroQol--a new facility for the measurement of health-related quality of life.Health policy, 16 3
-
R. Derwand, M. Scholz (2020)
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?Medical Hypotheses, 142
-
A. Cavalcanti, F. Zampieri, R. Rosa, L. Azevedo, V. Veiga, Á. Avezum, L. Damiani, A. Marcadenti, L. Kawano-Dourado, T. Lisboa, Debora Junqueira, P. Silva, L. Tramujas, E. Abreu-Silva, L. Laranjeira, A. Soares, L. Echenique, A. Pereira, F. Freitas, O. Gebara, Vicente Dantas, R. Furtado, E. Milan, N. Golin, F. Cardoso, I. Maia, C. Filho, A. Kormann, Roberto Amazonas, M. Oliveira, A. Serpa-Neto, M. Falavigna, R. Lopes, F. Machado, O. Berwanger (2020)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19The New England Journal of Medicine
-
M. Herdman, C. Gudex, Andrew Lloyd, M. Janssen, Paul Kind, David Parkin, G. Bonsel, Xavier Badia (2011)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 20
-
Ming Zhao (2020)
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodiesInternational Journal of Antimicrobial Agents, 55
-
J. Casey, N. Johnson, M. Semler, S. Collins, N. Aggarwal, R. Brower, Steven Chang, John Eppensteiner, M. Filbin, K. Gibbs, A. Ginde, M. Gong, F. Harrell, D. Hayden, C. Hough, Akram Khan, Lindsay Leither, M. Moss, C. Oldmixon, P. Park, L. Reineck, N. Ringwood, B. Robinson, D. Schoenfeld, N. Shapiro, J. Steingrub, Donna Torr, A. Weissman, C. Lindsell, T. Rice, B. Thompson, Samuel Brown, W. Self (2020)
Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19Annals of the American Thoracic Society, 17
-
WHO R&D blueprint: novel coronavirus: COVID-19 therapeutic trial synopsis -
N. Yehya, M. Harhay, M. Curley, D. Schoenfeld, R. Reeder (2019)
Reappraisal of Ventilator-Free Days in Critical Care ResearchAmerican Journal of Respiratory and Critical Care Medicine, 200
-
M. Hoffmann, Kirstin Mösbauer, Heike Hofmann-Winkler, A. Kaul, Hannah Kleine-Weber, Nadine Krüger, N. Gassen, M. Müller, C. Drosten, S. Pöhlmann (2020)
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2Nature, 585
-
C. E. (2020)
WHO Coronavirus Disease (COVID-19) Dashboard -
E. Schrezenmeier, T. Dörner (2020)
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatologyNature Reviews Rheumatology, 16
-
M. Scholz, R. Derwand (2020)
Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine to Win Todays Battle Against COVID-19? -
Rui Wang, S. Lagakos, J. Ware, David Hunter, J. Drazen (2007)
Statistics in medicine--reporting of subgroup analyses in clinical trials.The New England journal of medicine, 357 21
-
Roden (2020)
Considerations for drug interactions on QTc in exploratory COVID-19 treatment.Circulation, 141
-
P. Gautret, J. Lagier, P. Parola, V. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. Vieira, H. Dupont, S. Honoré, P. Colson, E. Chabrière, B. Scola, J. Rolain, P. Brouqui, D. Raoult (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 56
-
J. Fine, R. Gray (1999)
A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 94
-
J. Beigel, K. Tomashek, L. Dodd (2020)
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.The New England journal of medicine, 383
-
D. Roden, R. Harrington, A. Poppas, A. Russo (2020)
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatmentHeart Rhythm, 17
-
É. Azoulay, J. Waele, R. Ferrer, T. Staudinger, M. Borkowska, P. Póvoa, K. Iliopoulou, A. Artigas, S. Schaller, M. Shankar-Hari, M. Pellegrini, M. Darmon, J. Kesecioglu, M. Cecconi (2020)
International variation in the management of severe COVID-19 patientsCritical Care, 24
-
J. Beigel, K. Tomashek, L. Dodd, A. Mehta, B. Zingman, A. Kalil, E. Hohmann, H. Chu, A. Luetkemeyer, S. Kline, D. Castilla, R. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T. Patterson, R. Paredes, D. Sweeney, W. Short, G. Touloumi, D. Lye, N. Ohmagari, M. Oh, G. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M. Kortepeter, R. Atmar, C. Creech, J. Lundgren, A. Babiker, S. Pett, J. Neaton, T. Burgess, Tyler Bonnett, Michelle Green, M. Makowski, A. Osinusi, S. Nayak, H. Lane (2020)
Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine
-
Jia Liu, Ruiyuan Cao, Mingyue Xu, Xi Wang, Huanyu Zhang, Hengrui Hu, Yufeng Li, Zhìhóng Hú, Wu Zhong, Manli Wang (2020)
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 6
-
P. Maisonnasse, J. Guedj, V. Contreras, S. Behillil, C. Solas, R. Marlin, Thibaut Naninck, A. Pizzorno, Julien Lemaitre, António Gonçalves, Nidhal Kahlaoui, O. Terrier, R. Fang, V. Enouf, N. Dereuddre-Bosquet, Angela Brisebarre, F. Touret, C. Chapon, B. Hoen, B. Lina, Manuel Calatrava, S. Werf, X. Lamballerie, R. Grand (2020)
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primatesNature, 585
-
(2020)
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19: statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY -
Manli Wang, Ruiyuan Cao, Lei-ke Zhang, Xinglou Yang, Jia Liu, Mingyue Xu, Z. Shí, Zhìhóng Hú, Wu Zhong, Gengfu Xiao (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 30
-
Coronavirus resource center -
M. Shankar-Hari, Gary Phillips, M. Levy, C. Seymour, Vincent Liu, C. Deutschman, D. Angus, G. Rubenfeld, M. Singer (2016)
Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA, 315 8
- Publisher
- American Medical Association
- Copyright
- Copyright 2020 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2020.22240
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionDoes treatment with hydroxychloroquine improve clinical outcomes of adults hospitalized with coronavirus disease 2019 (COVID-19)? FindingsIn this randomized clinical trial that included 479 hospitalized adults with respiratory symptoms from COVID-19, the distribution of the day 14 clinical status score (measured using a 7-category ordinal scale) was not significantly different for patients randomized to receive hydroxychloroquine compared with placebo (adjusted odds ratio, 1.02). MeaningThese findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.
Journal
JAMA – American Medical Association
Published: Dec 1, 2020